BC Extra | May 22, 2019
Clinical News

May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

Lilly's mirikizumab meets in Phase II for Crohn’s  Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week 12 vs....
BC Week In Review | Feb 15, 2019
Company News

Mylan launches first U.S. generic of GSK's Advair

Mylan N.V. (NASDAQ:MYL) launched Wixela Inhub salmeterol/fluticasone, the first generic version of Advair Diskus, in the U.S. at a list price 70% less than the branded version. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) markets Advair Diskus. Both...
BC Week In Review | Feb 15, 2019
Company News

ZappRx, Teva partner to increase patient access to specialty respiratory drugs

The Teva Respiratory LLC unit of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to streamline prescription of Teva’s specialty respiratory medications. Financial terms were...
BC Week In Review | Feb 1, 2019
Clinical News

Mylan gets first FDA approval for an Advair generic

FDA approved Wixela Inhub salmeterol/fluticasone from Mylan N.V. (NASDAQ:MYL), the first generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), to treat asthma or chronic obstructive pulmonary disease (COPD). Mylan plans to launch the...
BC Week In Review | Jun 15, 2018
Clinical News

Mylan expecting another delay for generic Advair

Mylan N.V. (NASDAQ:MYL) said it expects to receive a second complete response letter from FDA for an ANDA of a generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK). Any delay would be a...
BC Extra | Jun 14, 2018
Company News

Mylan expecting another delay for generic Advair

Mylan N.V. (NASDAQ:MYL) said it expects to receive a second complete response letter from FDA for an ANDA of a generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK). Any delay would be a...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BC Week In Review | Feb 16, 2018
Clinical News

Sandoz gets CRL for generic Advair

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said it is “highly unlikely” that it will be able to launch its version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in the U.S. this year...
BC Extra | Feb 8, 2018
Company News

GSK breathes easier after delay for Sandoz’s generic Advair

Sandoz said it is “highly unlikely” that it will be able to launch its version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in the U.S. this year as planned after the Novartis AG (NYSE:NVS;...
BC Week In Review | Jan 12, 2017
Clinical News

LIPO-202: Ph II LIPO-202-CL-31 started

Neothetics began the double-blind, placebo-controlled, U.S. Phase II LIPO-202-CL-31 trial to evaluate 0.3 and 3 µg doses of subcutaneous LIPO-202 weekly for 8 weeks in about 150 patients. Neothetics Inc. (NASDAQ:NEOT), San Diego, Calif.  Product:...
Items per page:
1 - 10 of 192